These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Deihimi S; Lev A; Slifker M; Shagisultanova E; Xu Q; Jung K; Vijayvergia N; Ross EA; Xiu J; Swensen J; Gatalica Z; Andrake M; Dunbrack RL; El-Deiry WS Oncotarget; 2017 Jun; 8(25):39945-39962. PubMed ID: 28591715 [TBL] [Abstract][Full Text] [Related]
3. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
4. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature. Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330 [TBL] [Abstract][Full Text] [Related]
5. Does tumorigenesis select for or against mutations of the DNA repair-associated genes BRCA2 and MRE11?: considerations from somatic mutations in microsatellite unstable (MSI) gastrointestinal cancers. van der Heijden MS; Brody JR; Elghalbzouri-Maghrani E; Zdzienicka MZ; Kern SE BMC Genet; 2006 Jan; 7():3. PubMed ID: 16417627 [TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature. Zeinalian M; Emami MH; Salehi R; Naimi A; Kazemi M; Hashemzadeh-Chaleshtori M J Gastrointest Cancer; 2015 Jun; 46(2):118-25. PubMed ID: 25722176 [TBL] [Abstract][Full Text] [Related]
7. High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine. Gatalica Z; Vranic S; Xiu J; Swensen J; Reddy S Fam Cancer; 2016 Jul; 15(3):405-12. PubMed ID: 26875156 [TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of DNA mismatch repair-deficient colorectal cancer. Stadler ZK Hematol Oncol Clin North Am; 2015 Feb; 29(1):29-41. PubMed ID: 25475571 [TBL] [Abstract][Full Text] [Related]
9. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113 [TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Poynter JN; Siegmund KD; Weisenberger DJ; Long TI; Thibodeau SN; Lindor N; Young J; Jenkins MA; Hopper JL; Baron JA; Buchanan D; Casey G; Levine AJ; Le Marchand L; Gallinger S; Bapat B; Potter JD; Newcomb PA; Haile RW; Laird PW; Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3208-15. PubMed ID: 18990764 [TBL] [Abstract][Full Text] [Related]
11. Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations. Egoavil CM; Montenegro P; Soto JL; Casanova L; Sanchez-Lihon J; Castillejo MI; Martinez-Canto A; Perez-Carbonell L; Castillejo A; Guarinos C; Barbera VM; Jover R; Paya A; Alenda C Pathology; 2011 Apr; 43(3):228-33. PubMed ID: 21436632 [TBL] [Abstract][Full Text] [Related]
12. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer. Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389 [TBL] [Abstract][Full Text] [Related]
13. Approval of pembrolizumab for first-line treatment of microsatellite instability-high/mismatch repair deficient colorectal cancer: estimation of incremental benefit based on restricted mean survival time. Messori A Eur J Gastroenterol Hepatol; 2021 May; 33(5):763. PubMed ID: 33787545 [No Abstract] [Full Text] [Related]
14. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. Carethers JM; Stoffel EM World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352 [TBL] [Abstract][Full Text] [Related]